Provided by Tiger Trade Technology Pte. Ltd.

Biogen

221.64
-1.1800-0.53%
Volume:200.72K
Turnover:44.53M
Market Cap:32.72B
PE:39.37
High:224.08
Open:222.98
Low:220.41
Close:222.82
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:0.50
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.74
PE(LYR):25.22

Loading ...

Biogen Inc. Stock Falls 2.9%, Underperforms Peers

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Biogen, Bloom, First Solar, Oklo, NNE Trending With Analysts

TIPRANKS
·
Jul 18

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 18

Movement Alert|Biogen Rises 5.03% in Regular Trading, Canada Drug Agency Recommends Leqembi for Public Insurance Coverage

Market Focus
·
Jul 17

Eisai Limited: Cda-amc Recognizes Clinical Value of Leqembi & Recommends Public Coverage for Early Alzheimer's Disease

THOMSON REUTERS
·
Jul 16

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 16

Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO

Stock News
·
Jul 15

Biogen Names Michael Parini Chief Legal Officer Effective Aug. 3

Reuters
·
Jul 15

Biogen Appoints Michael J. Parini as Chief Legal Officer

THOMSON REUTERS
·
Jul 15

Biogen: CELIA Phase 2 Data Underpin Continued Confidence in Diranersen; Buy Rating and $256 Price Target Reiterated

TIPRANKS
·
Jul 15

Biogen Inc. Stock Slips 8.2%, Underperforms Peers

Dow Jones
·
Jul 15

IBM, Goldman Sachs, SK Hynix, Micron, Crowdstrike, Biogen, and More Stocks That Explain Today's Market

Dow Jones
·
Jul 15

Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206

MT Newswires Live
·
Jul 15

Biogen Stock Sinks on Lackluster Alzheimer's News

Dow Jones
·
Jul 14

RBC says Biogen detailed Phase 2 results ‘leave more questions than answers’

TIPRANKS
·
Jul 14

Biogen to face questions on safety and dose response, says Stifel

TIPRANKS
·
Jul 14

Eisai, Biogen announce presentation of results from real-world LEADER study

TIPRANKS
·
Jul 14

Leqembi® Real-world Leader Study Presented at Aaic® 2026 Finds over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved over an Average of 17 Months of Treatment

THOMSON REUTERS
·
Jul 14

Movement Alert|Biogen Falls 7.06% in Regular Trading, Diranersen Phase 2 CELIA Full Data Reveals Missed Primary Endpoint Sparking Registration Path Concerns

Market Focus
·
Jul 14